Skip to main content

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)

Baby being fed food

Study Overview: The primary objective of this study is to determine if a study medication called omalizumab (Xolair) alone or combined with oral immunotherapy may help people with multiple food allergies
Who Can Participate: Ages 1-55 years who have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut
Contact Information: Lauren Herlihy | (919) 962-4406 | Email-
For more information, click here


Systems Biology of Early Atopy (SUNBEAM)

Study Overview: We want to learn more about what factors put babies and toddlers at higher risk for developing food allergies and eczema. This is an observational research study, which means we will follow you and your child from birth to 3 years to learn more about how allergies develop.
Who Can Participate: Anyone who is 18 years or older, is currently pregnant, and is planning to deliver at UNC
Estimated Time Commitment: Approximately 3 years
Contact Information: Contact the study team at
For more information, click here

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Study Overview: The primary objective of this study is to learn more about ligelizumab as an injection treatment for peanut allergy
Who Can Participate: Children and adults aged 6-55 years
Contact Information: Emily English | (919) 962-4961 |
For more information, click here


  • A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study  (ARC008) [more]
  • EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) [more]
  • ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (Harmony) [more]
Interested in Participating in a Study?